Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1810 results
December 2016
-
Media Release
Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work
Findings across six countries and four continents showed a reduction in quality of life for majority (71%) of patients living with myeloproliferative neoplasms (MPNs)[1] Patients… -
Media Release
New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product
ASSIST-FL trial demonstrates equivalent safety, efficacy, pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar rituximab (GP2013) to the reference product[1] Interim data in over… -
Media Release
Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
82% (41 of 50) of patients achieved complete remission or complete remission with incomplete blood count recovery in interim analysis of Novartis study (ELIANA) ELIANA, the first global CAR T… -
Media Release
Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study
SEG101 reduced annual rate of sickle cell-related pain crises (SCPC) by 45.3% compared to placebo in patients with or without hydroxyurea therapy SEG101 is a potential new disease-… -
Story From Our Labs
How Zika infects the growing brain
The fast-spreading virus can take multiple routes into developing human nerve cells.
-
Story Discovery
Killing three diseases with one stone in the lab
Novartis researchers have discovered a compound that is showing promise against three parasites that cause three neglected diseases.
November 2016
-
In The News
New strategies for improving access in lower-income countries
Humanosphere highlights the work Novartis Access is doing to find a social enterprise solution to help patients in lower-income countries get access to medicines for chronic diseases. -
Story Discovery
Women in Science: Lilli Petruzzelli
A lung cancer researcher describes her journey toward a career in science at Novartis.
-
Media Release
Novartis Access communique son bilan à un an et annonce la signature d'un protocole d'accord avec le Rwanda
Le Rwanda devient le troisième pays à lancer Novartis Access, un programme de distribution de médicaments pour traiter les maladies chroniques dans les pays à faible revenu. Les premières livraisons… -
Media Release
Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
Rwanda becomes third country to launch Novartis Access portfolio against chronic diseases with first deliveries planned in early 2017 Since September 2015, Novartis Access has delivered more than… -
Media Release
Novartis Access informiert über Erfahrungen im ersten Jahr und gibt Memorandum of Understanding mit Ruanda bekannt
Ruanda ist das dritte Land, welches das Portfolio von Novartis Access gegen chronische Krankheiten einführen wird. Die ersten Medikamentenlieferungen sind für Anfang 2017 geplant. Seit September… -
In The News
Novartis Access one-year report
The Novartis Access one-year report describes first results, early learnings and challenges from our first twelve months on the ground. It also includes external perspectives and country updates,…